Developer docs
API playgroundTry for free, no card

Search company profiles

Islet Sciences

Full company profile

uuid003pei4

Namestring
Islet Sciences
Company typeenum
Private
Founded yearint
1994
Descriptiontext

Islet Sciences is a for-profit, Raleigh, North Carolina-based biotechnology company founded in 1994 that is developing a vialed suspension of micro-encapsulated porcine islets intended for injection into the abdominal cavity, a xenotransplantation-based approach targeting insulin-dependent diabetes. The company's core technology centers on micro-encapsulation of porcine islet cells, a biologic-device platform positioned for a regulated FDA pathway rather than a software or device-software product. Its capital-markets history includes a listing transition to OTC Pink under symbol ISLT, and its corporate domain isletsciences.com is currently listed for sale on HugeDomains, indicating operational discontinuity or dormant status.

The company's business model is not commercially active in the input data: there are no disclosed customers, no pricing model, no product launch milestones, and no revenue figures. Documented strategic activity is limited to the February 2012 acquisition of DiaKine Therapeutics and a single $695,000 funding round in February 2014. Leadership on record consists of Rick Egan as CFO and William Wilkison as COO, and headcount is reported in the 11-50 employee band. No AI/ML capabilities, partnerships, certifications, or regulatory milestones beyond the implied biologics pathway are evidenced.

Short descriptiontext

Islet Sciences is a Raleigh-based biotech developing micro-encapsulated porcine islet cell suspensions for abdominal injection to treat insulin-dependent diabetes. The company is delisted to OTC Pink and appears pre-commercial with no disclosed revenue or customers.

Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersRaleigh, United States
HQ citystring
Raleigh
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
cell therapy, diabetes treatment, xenotransplantation, encapsulated islets, biotech therapeutics
Industry1 code
PRIMARYHLAHAHAC
Patch Pumps & Wearable Insulin Delivery
Healthcare & Life Sciences/Medical Devices & Diagnostics/Diabetes Care Devices (CGM, Insulin Delivery)
NAICS code1 code
  • Surgical Appliance and Supplies Manufacturing339113
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Pharmaceutical Preparations2834
Product category
Cell Therapy Biologics
Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Islet Sciences develops a vialed suspension of micro-encapsulated porcine islets intended for injection into the abdominal cavity, focused on a cell-based therapeutic approach for diabetes. The company's work centers on xenogeneic islet cell encapsulation as a potential treatment modality for insulin-dependent patients.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1Micro-encapsulated Porcine Islet Suspension
Recent move3 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight2 records

Each record includes

Type, Description

Peers8 records
1ViaCyte
TypeDirect peer
Description

ViaCyte is the most directly comparable peer — a cell therapy developer of encapsulated stem-cell-derived islet cells (PEC-Direct, VC-02) implanted for Type 1 diabetes. It targets the same encapsulated-islet-for-diabetes category that Islet Sciences is pursuing, though ViaCyte uses stem-cell-derived rather than xenogeneic porcine islets.

2Sernova Biotherapeutics
TypeDirect peer
Description

Sernova develops an implantable Cell Pouch system with donor islets (and increasingly stem-cell-derived cells) for Type 1 diabetes. It competes in the same cell replacement therapy category and pursues a similar immune-isolation strategy for sustained insulin independence.

3Vertex Pharmaceuticals (VX-880 / CTX211)
TypeBroad incumbent
Description

Vertex acquired Semma Therapeutics and is advancing stem-cell-derived islet cell therapy (VX-880 / zimislecel) for Type 1 diabetes. It is a broad incumbent now leading the encapsulated/encapsulated-equivalent islet therapy race and a benchmark for the category Islet Sciences targets.

4Beta-O2 Technologies
TypeEmerging player
Description

Beta-O2 develops the ßAir macroencapsulation device for implantation of allogeneic islet cells, providing immune isolation for Type 1 diabetes. It is an emerging player in the same encapsulated islet cell therapy space with a smaller scale and earlier stage than Islet Sciences' lead asset.

5Defymed
TypeEmerging player
Description

Defymed is developing the MailPan macroencapsulation device for pancreatic cell transplantation in diabetes. It is an emerging European player in the same encapsulated-cell-therapy-for-diabetes category with a device-centric rather than cell-centric approach.

6PharmaCyte Biotech
TypeEmerging player
Description

PharmaCyte is developing a cellulose-based live-cell encapsulation technology (Cell-in-a-Box) applied initially to insulin-producing cells for diabetes. It is an emerging player using a comparable encapsulation platform strategy in the same therapeutic area.

7Dexcom
TypeOthers
Description

Dexcom is a leading continuous glucose monitor (CGM) manufacturer and serves the same Type 1 diabetes end patient. It is not a direct competitor to Islet Sciences' cell therapy but is the standard-of-care diagnostic/adjunct device that any islet replacement therapy would be benchmarked against.

8Tandem Diabetes Care
TypeOthers
Description

Tandem develops insulin pumps and automated insulin delivery systems for Type 1 diabetes. It is an adjacent device player that addresses the same patient population through the alternative insulin-pump pathway rather than cell replacement.

Market position
Strengths3 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights4 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Islet Sciences

Cell Therapy Biologicsisletsciences.com

Islet Sciences is a Raleigh-based biotech developing micro-encapsulated porcine islet cell suspensions for abdominal injection to treat insulin-dependent diabetes. The company is delisted to OTC Pink and appears pre-commercial with no disclosed revenue or customers.

What Islet Sciences does

Islet Sciences is a for-profit, Raleigh, North Carolina-based biotechnology company founded in 1994 that is developing a vialed suspension of micro-encapsulated porcine islets intended for injection into the abdominal cavity, a xenotransplantation-based approach targeting insulin-dependent diabetes. The company's core technology centers on micro-encapsulation of porcine islet cells, a biologic-device platform positioned for a regulated FDA pathway rather than a software or device-software product. Its capital-markets history includes a listing transition to OTC Pink under symbol ISLT, and its corporate domain isletsciences.com is currently listed for sale on HugeDomains, indicating operational discontinuity or dormant status.

The company's business model is not commercially active in the input data: there are no disclosed customers, no pricing model, no product launch milestones, and no revenue figures. Documented strategic activity is limited to the February 2012 acquisition of DiaKine Therapeutics and a single $695,000 funding round in February 2014. Leadership on record consists of Rick Egan as CFO and William Wilkison as COO, and headcount is reported in the 11-50 employee band. No AI/ML capabilities, partnerships, certifications, or regulatory milestones beyond the implied biologics pathway are evidenced.

Islet Sciences firmographics

Firmographics
Name
Islet Sciences
Website
https://isletsciences.com
Company type
Private
Founded year
1994
Headcount range
1–10 employees
Short description
Islet Sciences is a Raleigh-based biotech developing micro-encapsulated porcine islet cell suspensions for abdominal injection to treat insulin-dependent diabetes. The company is delisted to OTC Pink and appears pre-commercial with no disclosed revenue or customers.
Ownership category
akta.pro rank

Islet Sciences industry classification

Industry
Product category
Cell Therapy Biologics
NAICS
Surgical Appliance and Supplies Manufacturing (339113)
SIC
Surgical & Medical Instruments & Apparatus (3841), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAHAHAC
Patch Pumps & Wearable Insulin Delivery
Healthcare & Life Sciences/Medical Devices & Diagnostics/Diabetes Care Devices (CGM, Insulin Delivery)

Keywords

  • Cell therapy
  • Diabetes treatment
  • Xenotransplantation
  • Encapsulated islets
  • Biotech therapeutics

Where Islet Sciences is headquartered

Location

Headquarters

HQ city
Raleigh
HQ country
United States
HQ region
North America

Markets served

Islet Sciences business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations

Islet Sciences product offering

Product offering

Core offering

Islet Sciences develops a vialed suspension of micro-encapsulated porcine islets intended for injection into the abdominal cavity, focused on a cell-based therapeutic approach for diabetes. The company's work centers on xenogeneic islet cell encapsulation as a potential treatment modality for insulin-dependent patients.

Differentiator

Problem solved

Functional benefit

Products and services

  • Micro-encapsulated Porcine Islet Suspension

Companies that use Islet Sciences

Customer profile

Ideal customer profiles1 record

Islet Sciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Islet Sciences partnerships and signals

Strategic signal

Recent moves3 records

Expansion highlights2 records

Islet Sciences competitors and assessment

Company assessment

Direct peers

  • ViaCyte: ViaCyte is the most directly comparable peer — a cell therapy developer of encapsulated stem-cell-derived islet cells (PEC-Direct, VC-02) implanted for Type 1 diabetes. It targets the same encapsulated-islet-for-diabetes category that Islet Sciences is pursuing, though ViaCyte uses stem-cell-derived rather than xenogeneic porcine islets.
  • Sernova Biotherapeutics: Sernova develops an implantable Cell Pouch system with donor islets (and increasingly stem-cell-derived cells) for Type 1 diabetes. It competes in the same cell replacement therapy category and pursues a similar immune-isolation strategy for sustained insulin independence.

Broad incumbents

  • Vertex Pharmaceuticals (VX-880 / CTX211): Vertex acquired Semma Therapeutics and is advancing stem-cell-derived islet cell therapy (VX-880 / zimislecel) for Type 1 diabetes. It is a broad incumbent now leading the encapsulated/encapsulated-equivalent islet therapy race and a benchmark for the category Islet Sciences targets.

Emerging players

  • Beta-O2 Technologies: Beta-O2 develops the ßAir macroencapsulation device for implantation of allogeneic islet cells, providing immune isolation for Type 1 diabetes. It is an emerging player in the same encapsulated islet cell therapy space with a smaller scale and earlier stage than Islet Sciences' lead asset.
  • Defymed: Defymed is developing the MailPan macroencapsulation device for pancreatic cell transplantation in diabetes. It is an emerging European player in the same encapsulated-cell-therapy-for-diabetes category with a device-centric rather than cell-centric approach.
  • PharmaCyte Biotech: PharmaCyte is developing a cellulose-based live-cell encapsulation technology (Cell-in-a-Box) applied initially to insulin-producing cells for diabetes. It is an emerging player using a comparable encapsulation platform strategy in the same therapeutic area.

Others

  • Dexcom: Dexcom is a leading continuous glucose monitor (CGM) manufacturer and serves the same Type 1 diabetes end patient. It is not a direct competitor to Islet Sciences' cell therapy but is the standard-of-care diagnostic/adjunct device that any islet replacement therapy would be benchmarked against.
  • Tandem Diabetes Care: Tandem develops insulin pumps and automated insulin delivery systems for Type 1 diabetes. It is an adjacent device player that addresses the same patient population through the alternative insulin-pump pathway rather than cell replacement.

Market position

Strengths3 records

Weaknesses4 records

Competitive moat2 records

Key risks5 records

Key highlights4 records

Customer concentration

Islet Sciences social profiles

Digital presence

Islet Sciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Islet Sciences leadership team

Management profile

Number of profiles

Profiles2 records

Islet Sciences funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Islet Sciences M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Islet Sciences

What does Islet Sciences do?

Islet Sciences develops a vialed suspension of micro-encapsulated porcine islets intended for injection into the abdominal cavity, focused on a cell-based therapeutic approach for diabetes. The company's work centers on xenogeneic islet cell encapsulation as a potential treatment modality for insulin-dependent patients.

When was Islet Sciences founded?

Islet Sciences was founded in 1994. It employs 1 to 10 people.

Where is Islet Sciences based?

Islet Sciences is headquartered in Raleigh, United States, in the North America region.

Who are Islet Sciences's main competitors?

Direct peers on record are ViaCyte and Sernova Biotherapeutics. Vertex Pharmaceuticals (VX-880 / CTX211) is listed as a broad incumbent. Emerging players are Beta-O2 Technologies, Defymed and PharmaCyte Biotech. Others are Dexcom and Tandem Diabetes Care.

Does Islet Sciences have an API?

No public API is recorded for Islet Sciences.

What industry is Islet Sciences in?

Islet Sciences's product category is Cell Therapy Biologics. Its primary akta.pro industry code is HLAHAHAC, Patch Pumps & Wearable Insulin Delivery. Its NAICS code is 339113 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireIslet Sciences, Inc. Presented at 50th International Liver ConferenceIslet Sciences' COO presented remogliflozin etabonate's effects on insulin resistance and liver enzymes at the 50th International Liver Conference. The drug improved insulin sensitivity by 6-33% and reduced ALT by 32-42% in a phase 2b study. A phase 2b NASH study is anticipated to start in 2015.GlobeNewswireIslet Sciences, Inc. COO to Present at Metabolic Leaders ForumIslet Sciences COO Dr. William Wilkison will present remogliflozin etabonate data at the Metabolic Leaders Forum in Boston on March 24. The SGLT2 inhibitor showed HbA1c lowering >1% in phase 2b trials with low infection rates and no significant LDL-c increase. A phase 2b NASH study is anticipated to start in 2015.GlobeNewswireIslet Sciences, Inc. COO to Present at EASL: Remogliflozin Etabonate as Novel Treatment for Non-alcoholic Steatohepatitis (NASH)Islet Sciences' COO will present data on remogliflozin etabonate at EASL in Vienna, highlighting its SGLT2 inhibition and antioxidant activity for NASH. The drug is expected to enter phase 2b for NASH in 2015, with clinical site selection underway.GlobeNewswireIslet Sciences, Inc. Confirms Issuance of U.S. Patent for Using SGLT2 Inhibitors to Treat NASH/NAFLDIslet Sciences announced a U.S. patent allowance for its SGLT2 inhibitor remogliflozin etabonate, covering NASH/NAFLD treatment. The company entered an exclusive license agreement with Brighthaven Ventures, effective if it raises $10 million by May 31, 2015. A phase 2b NASH study is anticipated to commence in 2015.GlobeNewswireIslet Sciences, Inc. Announces Exclusive Licensing Agreement Between BHV Pharma and Libbs Farmaceutica to Develop and Commercialize SGLT2 Inhibitor Remogliflozin EtabonateBHV Pharma entered an exclusive licensing agreement with Libbs Farmaceutica to develop and commercialize SGLT2 inhibitor remogliflozin in Latin America, including Brazil. Libbs will pay an upfront $1.5 million and fund phase 2b development, with BHV receiving royalties or profit share. BHV expects to initiate the phase 2b study in late 2014.GlobeNewswireIslet Sciences, Inc. Receives Notice of Allowance for U.S. Patent Covering Novel IL-12 InhibitorsIslet Sciences received a USPTO notice of allowance for its patent on lisofylline analogs, which may be developed as IL-12 inhibitors for diabetes and NASH. The company is screening compounds and expects to continue development of its lead molecule ISLT-2669.GlobeNewswireIslet Sciences, Inc. Appoints William Wilkison, Ph.D. to Board of DirectorsIslet Sciences appointed Dr. William Wilkison, its COO, to the Board of Directors. Dr. Jonathan Lakey resigned from his positions to focus on islet transplantation research. The company also announced a binding letter of intent to acquire BHV Pharma.